iShares Gold Trust vs Smith & Nephew plc — how do they compare? iShares Gold Trust trades at $76.75, while Smith & Nephew plc trades at $30.2 (market cap $12.64B). The key difference: Smith & Nephew plc pays a 2.57% dividend while iShares Gold Trust pays none, and iShares Gold Trust is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| IAU | SNN | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $101.57 | $38.70 |
52-Week Low | $61.62 | $28.73 |
Market Cap | — | $12.64B |
Enterprise Value | — | $15.41B |
Dividend Yield | — | 2.57% |
Signals from Pluang's Aura AI — not financial advice
IAU, the iShares Gold Trust ETF, trades at $75.35, down 0.2% on the day. Technical indicators are bearish, with moving averages signaling a downtrend and key support at $75. Recent news highlights institutional activity, including a new position by Eurizon Asset Management Hungary Ltd. in Q1 2026, while broader gold sentiment is pressured by expectations of sustained higher interest rates.
The outlook for IAU is influenced by macroeconomic factors affecting gold. Higher-for-longer interest rate expectations from the Fed (WSJ, 2026-07-19) pose a headwind, but structural central bank buying (WSJ, 2026-07-16) offers support. The primary risk is gold's sensitivity to monetary policy, while the opportunity lies in its role as a hedge amid economic uncertainty.
Smith & Nephew (SNN) trades at $30.43, down 0.54% on the day, with mixed technical signals showing a neutral overall stance. The company demonstrates improving fundamentals with 2024 revenue of $5.81 billion and net income of $412 million, representing a 7.09% margin. Recent product launches including the LYNX COBLATION Wand and CORI XT robotics platform highlight ongoing innovation. Cash flow trends show strong operational performance with $987 million from operations in 2024.
SNN presents a balanced investment case with improving profitability and product innovation offset by recent earnings misses. The stock trades at reasonable valuations (P/E 21.36, P/S 2.17) with analyst consensus leaning Hold (68%). Key risks include execution challenges and competitive pressures, while catalysts include robotics expansion and wound care leadership. The $500 million buyback program supports shareholder returns.
Trailing returns across standard periods
Latest headlines on both assets
IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →